Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis
Open Access
- 1 August 2008
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 68 (8), 1316-1321
- https://doi.org/10.1136/ard.2007.086728
Abstract
Background: Macrophage migration inhibitory factor (MIF) has recently emerged as an important cytokine possibly linking rheumatoid arthritis (RA) and atherogenesis. Because atherogenesis is accelerated in RA this study was conducted to investigate whether anti-tumour necrosis factor (TNF) therapy could lead to sustained downregulation of systemic MIF levels and improvement in lipid profiles. Methods: Fifty RA patients with active disease (disease activity score in 28 joints (DAS28) ⩾3.2), who started adalimumab therapy at 40 mg every other week, were included. At baseline, weeks 16 and 52 serum levels of MIF and lipids were assessed. In addition, the DAS28 and serum C-reactive protein (CRP) levels and erythrocyte sedimentation rate (ESR) were determined. Results: After 16 weeks of adalimumab therapy, both DAS28 and MIF levels were significantly decreased (pConclusions: The results underline the sustained downregulation of MIF as a potential new mechanism by which anti-TNF therapy might reduce vascular inflammation, and as such perhaps cardiovascular morbidity in RA patients. This hypothesis is supported by an improved apo B/A-I ratio as well as reduced CRP levels in these patients.Keywords
This publication has 35 references indexed in Scilit:
- Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2007
- Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics RegisterArthritis & Rheumatism, 2007
- Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2007
- MIF production by dendritic cells is differentially regulated by Toll-like receptors and increased during rheumatoid arthritisCytokine, 2006
- Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 kinase, and NFκBBlood, 2006
- Anti-TNF therapy and plasma HDL cholesterol concentrationAtherosclerosis, 2005
- Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitisAnnals Of The Rheumatic Diseases, 2005
- Reduced leukocyte–endothelial cell interactions in the inflamed microcirculation of macrophage migration inhibitory factor–deficient miceArthritis & Rheumatism, 2004
- Inflammation in atherosclerosisNature, 2002
- Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritisArthritis & Rheumatism, 2000